Citations

Clear

219 citation(s) found for "Do, Ron".

Insulin Pulse Characteristics and Insulin Action in Non-diabetic Humans
LAURENTI, MARCELLO C. , Man, Chiara Dalla , Varghese, Ron T. , Andrews, James C. , Jones, John G. , Barosa, Cristina , Rizza, Robert A., Matveyenko, Aleksey V. , Nicolao, Giuseppe De , Bailey, Kent R. , Dalla Man, Chiara , Matveyenko, Aleksey V , Cobelli, Claudio , Vella, Adrian , Cobelli, Claudio , Vella, Adrian

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | February 21, 2021 | Volume: 106 | Issue: 6 | Pages: 1702-1709

10.1210/clinem/dgab100 | PMID 33606017 Get It

Abstract Objective Pulsatile insulin secretion is impaired in diseases such as type 2 diabetes that are characterized by insulin resistance. This has led to the suggestion that changes in insulin pulsatility directly impair insulin signaling. We sought to examine the effects of pulse characteristics on insulin action in humans, hypothesizing that a decrease in pulse amplitude or frequency is associated with impaired hepatic insulin action. Methods We studied 29 nondiabetic subjects on two occasions. On 1 occasion, hepatic and peripheral insulin action was measured using a euglycemic clamp. The deuterated water method was used to estimate the contribution of gluconeogenesis to endogenous glucose production. On a separate study day, we utilized nonparametric stochastic deconvolution of frequently sampled peripheral C-peptide concentrations during fasting to reconstruct portal insulin secretion. In addition to measuring basal and pulsatile insulin secretion, we used approximate entropy to measure orderliness and Fourier transform to measure the average, and the dispersion of, insulin pulse frequencies. Results In univariate analysis, basal insulin secretion (R2 = 0.16) and insulin pulse amplitude (R2 = 0.09) correlated weakly with insulin-induced suppression of gluconeogenesis. However, after adjustment for age, sex, and weight, these associations were no longer significant. The other pulse characteristics also did not correlate with the ability of insulin to suppress endogenous glucose production (and gluconeogenesis) or to stimulate glucose disappearance. Conclusions Overall, our data demonstrate that insulin pulse characteristics, considered independently of other factors, do not correlate with measures of hepatic and peripheral insulin sensitivity in nondiabetic humans.
Arrhythmias in Cardiac Sarcoidosis Bench to Bedside
Rosenfeld, Lynda E. , Chung, Mina K. , Harding, Clifford V. , Spagnolo, Paolo , Grünewald, Johan , Appelbaum, Jason, Sauer, William H. , Culver, Daniel A. , Joglar, José A. , Lin, Ben A. , Jellis, Christine , Dickfeld, Timm-Michael, Kwon, Deborah , Cremer, Paul , Bogun, Frank , Bock, Ashley, Mehta, Davendra, Leis, Paul, Siontis, Konstantinos C. , Kaufman, Elizabeth S. , Crawford, Thomas , Zimetbaum, Peter , Zishiri, Edwin , Ellenbogen, Kenneth A. , Quadri, Syed M. , Vincent, Logan , Kalbfleish, Steven, Murgatroyd, Francis , Birnie, David H. , Okada, David R. , Bhat, Pavan , Bellumkonda, Lavanya , Blankstein, Ron , Cheng, Richard K. , Estep, Jerry D. , Cremer, Paul C , Bellumkonda, Lavanya , Cheng, Richard , Ellenbogen, Kenneth A , Dickfeld, Timm-Michael L. , Miller, Edward J. , Kron, Jordana , Singh, Jagmeet P , Chrispin, Jonathan , Patton, Kristen K. , Callahan, Thomas D , Judson, Marc A. , Maulion, Christopher , Blankstein, Ron , Farr, Maryjane

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | February 16, 2021 | Volume: 14 | Issue: 2 | Pages: No page available

10.1161/circep.120.009203 | PMID 33591816 Get It

Cardiac sarcoidosis is a component of an often multiorgan granulomatous disease of still uncertain cause. It is being recognized with increasing frequency, mainly as the result of heightened awareness and new diagnostic tests, specifically cardiac magnetic resonance imaging and 18 F-fluorodeoxyglucose positron emission tomography scans. The purpose of this case-based review is to highlight the potentially life-saving importance of making the early diagnosis of cardiac sarcoidosis using these new tools and to provide a framework for the optimal care of patients with this disease. We will review disease mechanisms as currently understood, associated arrhythmias including conduction abnormalities, and atrial and ventricular tachyarrhythmias, guideline-directed diagnostic criteria, screening of patients with extracardiac sarcoidosis, and the use of pacemakers and defibrillators in this setting. Treatment options, including those related to heart failure, and those which may help clarify disease mechanisms are included.
Solitary Blood Cultures
Novis, David A., Dale, Jane C., Schifman, Ron B., Ruby, Stephen G., Walsh, Molly K.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | January 28, 2021 | Volume: 125 | Issue: 10 | Pages: 1290-1294

10.5858/2001-125-1290-sbc | PMID 11570903 Get It

Abstract Objective. —To determine the frequency with which solitary blood culture samples were submitted to laboratories serving small hospitals and to ascertain whether certain hospital practices relating to the performance of blood cultures were associated with lower solitary blood culture rates (SBCRs). Design. —Participants in the College of American Pathologists Q-Probes laboratory quality improvement program collected data prospectively on the numbers of solitary blood culture sets from adult patients submitted to their laboratories and answered questions about their institutions' practice characteristics relating to the collection of blood culture specimens. Setting and Participants. —Three hundred thirty-three public and private institutions with a median occupied bed size of 57. Participants were located in the United States (n = 329), Canada (n = 3), and Australia (n = 1). Main Outcome Measure. —The solitary blood culture rate was defined as the number of instances in which only 1 blood culture venipuncture was performed on an individual patient during a 24-hour period divided by the total number of blood culture venipunctures that were performed during the study period. Results. —Participants submitted data on 132 778 adult patient blood culture sets. The SBCRs were 3.4% or less in the top-performing 10% of participating institutions (90th percentile and above), 12.7% in the midrange of participating institutions (50th percentile), and 42.5% or more in the bottom-performing 10% of participating institutions (10th percentile and below). In half the participating institutions, the SBCRs for inpatients were 8.3% or less and for outpatients, 22% or less. Solitary blood culture rates were lower for institutions in which phlebotomists rather than nonphlebotomists routinely collected blood culture specimens, in which internal policies required drawing at least 2 blood culture sets, in which hospital personnel contacted clinicians when their laboratories received requests for solitary blood culture sets, and in which quality control programs monitored SBCRs routinely. Conclusions. —Hospitals can achieve SBCRs under 5%. Those hospitals with particularly high SBCRs may lower their rates by altering certain institutional practices.
Factors that contribute to the impairment of quality of life in gastroparesis
Parkman, Henry P. , Wilson, Laura , Yates, Katherine P. , Koch, Kenneth L. , Abell, Thomas L. , McCallum, Richard W. , Sarosiek, Irene , Kuo, Braden , Malik, Zubair , Schey, Ron , Shulman, Robert J. , Grover, Madhusudan , Farrugia, Gianrico , Miriel, Laura , Tonascia, James , Hamilton, Frank A., Pasricha, Pankaj J. , Parkman, H P , Abell, T L , Kuo, Braden

Mayo Clinic

Neurogastroenterology & Motility | January 25, 2021 | Volume: 33 | Issue: 8 | Pages: No page available

10.1111/nmo.14087 | PMID 33493377 Get It

AbstractBackgroundUnderstanding factors that impair quality of life (QOL) in gastroparesis is important for clinical management. Aims: (a) Determine QOL in patients with gastroparesis; (b) Determine factors that impair QOL.MethodsGastroparetic patientsAQ6 underwent history and questionnaires assessing symptoms (PAGI‐SYM and Rome III), QOL (SF‐36v2 and PAGI‐QOL), depression (Beck Depression Inventory [BDI]), and anxiety (State Trait Anxiety InventoryAQ7).Key Results715 gastroparesis patients (256 diabetic (DG), 459 idiopathic (IG)) were evaluated. SF‐36 physical component (PC) score averaged 33.3 ± 10.5; 41% had impaired score <30. SF‐36 PC scores were similar between diabetic and idiopathic gastroparesis. Impaired SF‐36 PC associated with increased nausea/vomiting and upper abdominal pain subscores, acute onset of symptoms, higher number of comorbidities, use of narcotic pain medications, and irritable bowel syndrome (IBS). SF‐36 mental component (MC) score averaged 38.9 ± 13.0; 26% had impaired score <30. Poor SF‐36 MC associated with diabetic etiology, higher Beck depression inventory, and state anxiety scores. PAGI‐QOL score averaged 2.6 ± 1.1; 50% had a score of <2.6. Low PAGI‐QOL associated with higher fullness, bloating, and upper abdominal pain subscores, more depression and Trait anxiety, smoking cigarettes, need for nutritional support, progressively worsening symptoms and periodic exacerbations.Conclusions & InferencesMultiple measures show poor QOL present in gastroparesis. Several areas impacted on reduced QOL: (a) Symptoms of nausea, vomiting, and abdominal pain, as well as IBS; (b) Etiology and acute onset and progressively worsening symptoms; (c) Comorbidities and psychological factors such as anxiety and depression; (d) Patient‐related factors such as smoking. Targeting the modifiable factors may improve patient outcomes in gastroparesis.
Multicenter Study of Long-Term Safety of Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease
Torres, Vicente E. , Chapman, Arlene B., Devuyst, Olivier , Gansevoort, Ron T. , Perrone, Ronald D. , Lee, Jennifer , Hoke, Molly E., Estilo, Alvin, Sergeyeva, Olga, Torres, Vicente E , Torres, Vicente E , Devuyst, Olivier; https://orcid.org/0000-0003-3744-4767

Mayo Clinic

Clinical Journal of the American Society of Nephrology | December 29, 2020 | Volume: 16 | Issue: 1 | Pages: 48-58

10.2215/cjn.10250620 | PMID 33376102 Get It

Background and objectives Tolvaptan slows kidney function decline in patients with autosomal dominant polycystic kidney disease (ADPKD) at risk of rapid progression. In the 3-year Tolvaptan Efficacy and Safety in Management of ADPKD and Its Outcomes (TEMPO) 3:4, 2-year extension to TEMPO 3:4 (TEMPO 4:4), and 1-year Replicating Evidence of Preserved Renal Function: An Investigation of Tolvaptan Safety and Efficacy in ADPKD (REPRISE) trials, aquaretic adverse events were common. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) elevations occurred in all three studies. Three patients met Hy Law criteria (ALT or AST more than three times and total bilirubin more than two times the upper limit of normal) for severe drug-induced liver injury (two in TEMPO 3:4 and one in TEMPO 4:4). In REPRISE, liver enzyme monitoring frequency was increased to monthly, with no Hy Law cases. A long-term, phase 3 safety study has further characterized tolvaptan safety. Design, setting, participants, & measurements Subjects who completed TEMPO 4:4, REPRISE, or other tolvaptan trials could enroll in this prospective, multinational, open-label safety study. Assessments included monthly liver enzyme testing during the first 18 months of tolvaptan exposure and every 3 months thereafter. Results Among 1803 subjects, median tolvaptan exposure during the extension was 651 days (interquartile range, 538–924), and cumulative exposure (extension and previous trials) was ≤11 years. Subjects entering from REPRISE placebo experienced more aquaretic adverse events compared with subjects from TEMPO 4:4 or REPRISE tolvaptan ( i.e ., patients with prior long-term tolvaptan exposure). Liver enzyme elevations also occurred more frequently in subjects from REPRISE placebo. Percentages experiencing ALT ≥3/≥5/ ≥10/≥20 times the upper limit of normal were 3.2%/2.1%/0.9%/0.7%, respectively, in subjects from REPRISE placebo and 0.6%–1.1%/0.0%–0.1%/0%/0%, respectively, in those from REPRISE tolvaptan and TEMPO 4:4. Percentages experiencing AST ≥3/ ≥5/≥10/≥20 times the upper limit of normal were 6.9%/3.8%/2.3%/0.8%, respectively, in subjects from REPRISE placebo and 0.9%–2.0%/0.0%–1.0%/0%/0%, respectively, in those from REPRISE tolvaptan and TEMPO 4:4. No Hy Law cases occurred. Conclusions No new safety signals emerged during this long-term extension. Monthly liver function testing for the first 18 months of treatment appeared to enable effective detection and management of transaminase elevations. Clinical Trial registry name and registration number: Open Label Extension of TEMPO 3:4, NCT02251275
Race and Regional Differences in Risk Factors for Cognitive Impairment From a Combined Cohort Analysis
Windham, B. Gwen , Griswold, Michael , Henegan, James, Petersen, Ron, Knopman, David S. , Lirette, Seth T. , Mielke, Michelle M. , Mosley, Thomas H.

Mayo Clinic

Innovation in Aging | December 18, 2020 | Volume: 4 | Issue: Supplement_1 | Pages: 781-782

10.1093/geroni/igaa057.2828 Get It

Abstract Few studies examined race-regional influences on mild cognitive impairment (MCI) and dementia risk factors. We examined 14 risk factors in 5 race-regions, e.g. cross-sectional age- and sex-adjusted relative prevalence ratios (RPR) from multinomial regression comparing associations of low education (&lt;12yrs) with MCI and dementia (versus normal cognition) across 3 race-region groups, average age 76yrs: whites in the Mayo Clinic Study of Aging[MCSA, Olmsted County, MN—MCSA-MN-Whites); Atherosclerosis Risk in Communities(ARIC) whites in suburban Minneapolis, MN—ARIC-MN-Whites); ARIC-African Americans in Jackson, MS—ARIC-MS-AA. Among 3,787 MCSA-Whites, low education exerted a 2-fold risk for MCI, RPR=2.09(95%CI: 1.57,2.78). Conversely, low education was not a supported MCI risk factor for ARIC-MN-Whites (n=1,901—RPR=0.63(0.31,1.28) or ARIC-MS-AA, (n=1,416—RPR=.0.81 (0.60,1.10)), with substantially differential race-region effects. Low education RPRs for dementia also differed by race-region: RPR=4.43(2.68,7.31-MCSA-MN-W), RPR=0.70 (0.16,2.99-ARIC-MN-Whites), and RPR=2.54 (1.74,3.72-ARIC-MS-AA). Understanding why risk factors differ by race and region likely requires diverse samples and harmonized methods using culturally-appropriate assessments.
‘A sword of Damocles’: patient and caregiver beliefs, attitudes and perspectives on presymptomatic testing for autosomal dominant polycystic kidney disease: a focus group study
Logeman, Charlotte , Sautenet, Bénédicte , Rangan, Gopala K. , Gutman, Talia , Craig, Jonathan C. , Ong, Albert , Chapman, Arlene B., Ahn, Curie , Coolican, Helen, Kao, Juliana Tze‐Wah , Gansevoort, Ron T., Harris, Tess , Torres, Vicente E. , Pei, York , Ryan, Jessica , Johnson, David W. , Viecelli, Andrea K. , Geneste, C., Howell, Martin , Ju, Angela, Manera, Karine , Teixeira‐Pinto, Armando , Parasivam, Gayathri, Ahn, Curie , Torres, Vincent, Howell, Martin , Torres, Vicente E , Johnson, David W , Ong, Albert C M , Cho, Yeoungjee , Perrone, Ronald D. , Fowler, Kevin John , Kerr, Peter G. , Kim, Hyunsuk , Kim, Yaerim , Tong, Allison

Mayo Clinic

BMJ Open | October 10, 2020 | Volume: 10 | Issue: 10 | Pages: e038005

10.1136/bmjopen-2020-038005 | PMID 33040007 Get It

Background and objectives Presymptomatic testing is available for early diagnosis of hereditary autosomal dominant polycystic kidney disease (ADPKD). However, the complex ethical and psychosocial implications can make decision-making challenging and require an understanding of patients’ values, goals and priorities. This study aims to describe patient and caregiver beliefs and expectations regarding presymptomatic testing for ADPKD. Design, setting and participants 154 participants (120 patients and 34 caregivers) aged 18 years and over from eight centres in Australia, France and Korea participated in 17 focus groups. Transcripts were analysed thematically. Results We identified five themes: avoiding financial disadvantage (insecurity in the inability to obtain life insurance, limited work opportunities, financial burden); futility in uncertainty (erratic and diverse manifestations of disease limiting utility, taking preventive actions in vain, daunted by perplexity of results, unaware of risk of inheriting ADPKD); lacking autonomy and support in decisions (overwhelmed by ambiguous information, medicalising family planning, family pressures); seizing control of well-being (gaining confidence in early detection, allowing preparation for the future, reassurance in family resilience); and anticipating impact on quality of life (reassured by lack of symptoms, judging value of life with ADPKD). Conclusions For patients with ADPKD, presymptomatic testing provides an opportunity to take ownership of their health through family planning and preventive measures. However, these decisions can be wrought with tensions and uncertainty about prognostic implications, and the psychosocial and financial burden of testing. Healthcare professionals should focus on genetic counselling, mental health and providing education to patients’ families to support informed decision-making. Policymakers should consider the cost burden and risk of discrimination when informing government policies. Finally, patients are recommended to focus on self-care from an early age.
Cystatin C regulates the cytotoxicity of infection‐induced endothelial‐derived β‐amyloid
Balczon, Ron , Morrow, K. Adam, Leavesley, Silas J. , Francis, C. Michael , Stevens, Trevor C., Agwaramgbo, Ezinne, Stevens, R.P. , Langham, Geri, Voth, S.B. , Cioffi, Eugene A., Weintraub, Susan, Stevens, Troy , Leavesley, Silas , Williams, Christopher, Weintraub, Susan T.

Mayo Clinic

FEBS Open Bio | October 8, 2020 | Volume: 10 | Issue: 11 | Pages: 2464-2477

10.1002/2211-5463.12997 | PMID 33030263 Get It

Infection of rat pulmonary microvascular endothelial cells with the bacterium Pseudomonas aeruginosa induces the production and release of cytotoxic oligomeric tau and beta amyloid (Aβ). Here, we characterized these cytotoxic amyloids. Cytotoxic behavior and oligomeric tau were partially resistant to digestion with proteinase K, but cytotoxicity was abolished by various denaturants including phenol, diethylpyrocarbonate (DEPC), and 1,1,1,3,3,3‐hexafluoro‐2‐isopropanol (HFIP). Ultracentrifugation for 8 h at 150 000 g was required to remove cytotoxic activity from the supernatant. Ultracentrifugation, DEPC treatment, and immunodepletion using antibodies against Aβ also demonstrated that cytoprotective protein(s) are released from endothelial cells during P. aeruginosa infection. Mass spectrometry of endothelial cell culture media following P. aeruginosa infection allowed identification of multiple potential secreted modulators of Aβ, including cystatin C, gelsolin, and ApoJ/clusterin. Immunodepletion, co‐immunoprecipitation, and ultracentrifugation determined that the cytoprotective factor released during infection of endothelial cells by P. aeruginosa is cystatin C, which appears to be in a complex with Aβ. Cytoprotective cystatin C may provide a novel therapeutic avenue for protection against the long‐term consequences of infection with P. aeruginosa.
Prospective Validation of the FLIPI: Baseline Distribution and Correlates in Newly Diagnosed Follicular Lymphoma (FL) Patients from the US: First Report of the National LymphoCare Study.
Dillon, Hildy, Feliciano, Susan, Friedberg, Jonathan W. , Hainsworth, John D. , Steis, Ron, Link, Brian K. , Cerhan, James R. , Farber, Charles Michael , Vose, Julie M. , Zelenetz, Andrew D.

Mayo Clinic

Blood | April 19, 2020 | Volume: 106 | Issue: 11 | Pages: 1000-1000

10.1182/blood.v106.11.1000.1000 Get It

Abstract Background: FL comprises one quarter of lymphoma in the United States, presents in a heterogeneous fashion, and generates substantial debate regarding optimal management strategies. The recently published clinical prognostic index (FLIPI, BLOOD104:1258) facilitates outcome evaluation and may guide therapeutic strategy. The National LymphoCare Study (NLCS) is an ongoing disease-based longitudinal observational study designed to assess patterns of initial disease presentation including prognosis, long term treatment choices, and clinical outcomes in FL patients. Methods: Beginning March, 2004, pts were recruited from U.S. community practices and academic centers. Pts with FL diagnosed within 6 months with no prior lymphoma history are eligible for enrollment. Collected data includes histology, staging and prognostic evaluation, serial management strategies including drug choices but not doses, response to treatment, and events including relapses and death. There is no study-specific prescribed treatment regimen or intervention. The treating physician determines management for FL according to clinical judgment. Results: 992 pts were enrolled from 207 sites through April, 2005. 182 community sites enrolled 86% of subjects. Pt characteristics include median age 62y, 52.5% female, 90.6% Caucasian, 40% Gr1, 26% Gr2, 19% Gr3, 13% NOS, with highest determined Ann Arbor stage = 17% I, 15%II, 26% III, 33%IV, 8% Unk. The demographic characteristics are similar to pts in the national SEER registry (median age 64, 51% F, 91.3% Caucasian) but clinical characteristics are notable for a higher fraction of advanced stage disease. 686/992 (69%) patients had calculable FLIPI scores based on initial investigator workup. Of factors contributing to FLIPI scores, LDH was collected by investigators in 78% of pts. When correlated with age, geography, and academic/community sites, LDH collection rates differ with 90% in academic sites vs 76% in community sites (p = .0002). Distribution of FLIPI among 686 pts with complete scores are shown in Table1, and show remarkable consistency across grades. Summary: The NLCS is an ongoing study with a large and rapidly growing database combining clinical and treatment data and is the first database investigating initial workup, prognosis, and outcomes of pts in a predominantly community based U.S. population. FL pts enrolled in NLCS are similar to those in the SEER database, and should be widely generalizable to the US population. FLIPI continues to define three distinct groups in the NLCS and is independent of histologic grade. Current evaluation patterns result in 31% incomplete FLIPI scores, suggesting this useful prognostic index is underutilized. FLIPI distribution (%) Low 36 37 37 38 34 81 14 Intermed 37 31 32 28 37 14 40 High 27 32 31 34 29 5 46 Solal Celigny n=1795 NLCS n=686 NLCS Gr1 n=276 NLCS Gr2 n=188 NLCS Gr3 n=136 Stage I/II n=234 Stage III/IV n=452
Center-level Variation in HLA-incompatible Living Donor Kidney Transplantation Outcomes
Jackson, Kyle R. , Bowring, Mary G. , Chen, Jennifer , Waldram, Madeleine M. , Benedetti, Enrico , Ratner, Lloyd E. , Kapur, Sandip , Pelletier, Ronald P. , Melcher, Marc L. , Singh, Pooja , Sudan, Debra L. , Posner, Marc P., El‐Amm, Jose M., Shapiro, Ron , Cooper, Matthew , Verbesey, Jennifer , Lipkowitz, George S. , Rees, Michael A. , Sankari, Bashir R., Gerber, David A. , Wellen, Jason R., Bozorgzadeh, Adel , Heher, Eliot , Weng, Francis L. , Helderman, J. Harold, Brayman, Kenneth L. , Oberholzer, José , Kozłowski, Tomasz , Covarrubias, Karina , Desai, Niraj M. , Massie, Allan B. , Segev, Dorry L. , Garonzik‐Wang, Jacqueline , Cooper, Matthew , Melcher, Marc L , Segev, Dorry L , Sudan, Debra L , Gerber, David A , Long, Jane J. , Motter, Jennifer D. , Orandi, Babak John , Montgomery, Robert A. , Stegall, Mark D. , Jordan, Stanley C. , Dunn, Ty B , Roberts, John P. , Marsh, Christopher L. , Gaber, A. Osama , Djamali, Arjang , Concepcion, Beatrice P.

Mayo Clinic

Transplantation | April 1, 2020 | Volume: 105 | Issue: 2 | Pages: 436-442

10.1097/tp.0000000000003254 | PMID 32235255 Get It

Background. Desensitization protocols for HLA-incompatible living donor kidney transplantation (ILDKT) vary across centers. The impact of these, as well as other practice variations, on ILDKT outcomes remains unknown. Methods. We sought to quantify center-level variation in mortality and graft loss following ILDKT using a 25-center cohort of 1358 ILDKT recipients with linkage to Scientific Registry of Transplant Recipients for accurate outcome ascertainment. We used multilevel Cox regression with shared frailty to determine the variation in post-ILDKT outcomes attributable to between-center differences and to identify any center-level characteristics associated with improved post-ILDKT outcomes. Results. After adjusting for patient-level characteristics, only 6 centers (24%) had lower mortality and 1 (4%) had higher mortality than average. Similarly, only 5 centers (20%) had higher graft loss and 2 had lower graft loss than average. Only 4.7% of the differences in mortality (P < 0.01) and 4.4% of the differences in graft loss (P < 0.01) were attributable to between-center variation. These translated to a median hazard ratio of 1.36 for mortality and 1.34 of graft loss for similar candidates at different centers. Post-ILDKT outcomes were not associated with the following center-level characteristics: ILDKT volume and transplanting a higher proportion of highly sensitized, prior transplant, preemptive, or minority candidates. Conclusions. Unlike most aspects of transplantation in which center-level variation and volume impact outcomes, we did not find substantial evidence for this in ILDKT. Our findings support the continued practice of ILDKT across these diverse centers.